» Articles » PMID: 31835073

Neck Management in Patients with Olfactory Neuroblastoma

Overview
Journal Oral Oncol
Publisher Elsevier
Specialty Dentistry
Date 2019 Dec 14
PMID 31835073
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Optimal neck management in patients with olfactory neuroblastoma (ONB), a rare malignancy, remains uncertain. This study aimed to analyse patterns of cervical lymph node metastases and corresponding clinical outcomes and to investigate the value of elective neck irradiation (ENI) in this population.

Methods And Materials: This study retrospectively reviewed clinical records, imaging findings, nodal metastasis features and treatment data of 217 patients with ONB treated at our hospital during 1991-2019. Univariate and multivariate analyses were used to assess the influence of cervical lymph node involvement on treatment outcomes. Survival and regional failure rates were compared between patients with or without ENI.

Results: Thirty-two patients (14.7%) presented initially with cervical lymph node metastases, most frequently at levels II (10.6%, 23/217) and VIIa (5.5%, 12/217). Patients with and without cervical node metastasis differed significantly in overall (OS) (41.9% vs. 86.1%, p < 0.001), progression-free (PFS) (41.9% vs. 84.8%, p < 0.001), regional failure-free (45.9% vs. 89%, p < 0.001) and distant metastasis-free survival (41.5% vs. 86.1%, p < 0.001). Cervical lymph involvement was an independent factor affecting poor OS (hazard ratio, 0.184, 95% confidence interval, 0.078-0.436, p < 0.001) and PFS (hazard ratio, 0.198, 95% confidence interval, 0.088-0.445, p < 0.001). Moreover, 43.8% patients (95/217) underwent ENI, which significantly reduced the incidence of regional recurrence from 10.7% to 3.2% (χ = 4.396, p = 0.036) but did not significantly affect other survival outcomes. Regional failures could be resolved using salvage treatment.

Conclusions: Our findings indicate the importance of systematic therapy for patients with initial cervical lymph node metastases. ENI is not recommended for N0 disease.

Citing Articles

Survival Analysis and Prognostic Factors After Endonasal Resection of Advanced Olfactory Neuroblastomas: A Single Institution Experience.

Song X, Yang J, Yuan C, Gu D, Wang L, Zhang Q J Otolaryngol Head Neck Surg. 2024; 53:19160216241267737.

PMID: 39164943 PMC: 11337177. DOI: 10.1177/19160216241267737.


Clinical outcomes for olfactory neuroblastoma.

Nakazono A, Motegi H, Suzuki M, Nakamaru Y, Yamaguchi S, Ishi Y Front Oncol. 2024; 14:1329572.

PMID: 38756668 PMC: 11096780. DOI: 10.3389/fonc.2024.1329572.


Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification.

Hu X, Zhou Y, Hill C, Chen K, Cheng C, Liu X Br J Cancer. 2024; 130(11):1841-1854.

PMID: 38553589 PMC: 7616008. DOI: 10.1038/s41416-024-02666-y.


Failure Patterns of Recurrence in Patients With Localized Esthesioneuroblastoma Following Surgery and Adjuvant Radiotherapy Without Elective Nodal Irradiation.

Katano A, Minamitani M, Ohira S, Yamashita H Cureus. 2023; 15(10):e46523.

PMID: 37927675 PMC: 10625395. DOI: 10.7759/cureus.46523.


Management of Esthesioneuroblastoma: A Retrospective Study of 6 Cases and Literature Review.

Alami Z, Farhane F, Bouziane A, Mhirech S, Amrani Joutei S, Hassani W Case Rep Oncol. 2022; 15(1):176-186.

PMID: 35431860 PMC: 8958627. DOI: 10.1159/000521736.